4-Aminobiphenyl and DNA Reactivity: Case Study Within the Context of the 2006 IPCS Human Relevance Framework for Analysis of a Cancer Mode of Action for Humans

REFERENCES

• al-Altrash J., Zhang Y. J., Lin D., Kadlubar F. F., Santella R. M. Quantitative immunohistochemical analysis of 4-aminobiphenyl-DNA cultured cells and mice: Comparison to gas chromatography/mass spectroscopy analysis. Chem. Res. Toxicol. 1995; 8: 747–752
   PubMedGoogle Scholar
• Auerbach O., Garfinkel L. Histologic changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer 1989; 64: 987–987
   Google Scholar
• Besaratinia A., Bates S. E., Pfeifer G. P. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: Inconsistency with the p53 mutational spectrum in bladder cancer. Cancer Res. 2002; 62: 4331–4338
   PubMedGoogle Scholar
• Block N. L., Sigel M. M., Lynne C. M., Ng A. B., Grosberg R. A. The initiation, progress, and diagnosis of dog bladder cancer induced by 4-aminobiphenyl. Invest. Urol. 1978; 16: 50–54
   PubMedGoogle Scholar
• Bonser G. M. Precancerous changes in the urinary bladder. In The Morphological Precursor of Cancer, L. Severi. University of Perugia, Perugia 1962; 435–54
   Google Scholar
• Bookland E. A., Reznikoff C. A., Lindstrom M., Swaminathan S. Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxy derivatives. Cancer Res. 1992a; 52: 1615–1621
   PubMedGoogle Scholar
• Bookland E. A., Swaminathan S., Oyasu R., Gilchrist K. W., Lindstrom M., Reznikoff C. A. Tumorigenic transformation and neoplastic progression of human uroepithelial cells after exposure in vitro to 4-aminobiphenyl or its metabolites. Cancer Res. 1992b; 52: 1606–1614
   PubMed Web of Science ®Google Scholar
• Bryant M. S., Vineis P., Skipper P. L., Tannenbaum S. R. Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco. Proc. Natl. Acad. Sci. USA 1988; 85: 9788–9791
   PubMed Web of Science ®Google Scholar
• Burger M. S., Torino J. L., Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ. Mol. Mutagen. 2001; 38: 1–11
   PubMedGoogle Scholar
• Butler M. A., Guengerich F. P., Kadlubar F. F. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res. 1989a; 49: 25–31
   PubMed Web of Science ®Google Scholar
• Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 1989b; 86: 7696–7700
   PubMed Web of Science ®Google Scholar
• Cairns P., Proctor A. J., Knowles M. A. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6: 2305–2309
   PubMed Web of Science ®Google Scholar
• Cairns T. The ED01 study: Introduction, objectives, and experimental design. J. Environ. Pathol. Toxicol. 1979; 3: 1–7
   PubMedGoogle Scholar
• Cartwright R. A., Rogers H. J., Barham-Hall D., Glashan R. W., Ahmad R. A, Higgins E., Kahn M. A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 16: 842–846
   Google Scholar
• Cascorbi I., Roots I., Brockmoller J. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: Significantly reduced risk in subjects with NAT1*10. Cancer Res. 2001; 61: 5051–5056
   PubMed Web of Science ®Google Scholar
• Castelao J. E., Yuan J. M., Skipper P. L., Tannenbaum S. R., Gago-Dominguez M., Crowder J. S., Ross R. K., Yu M. C. Gender-and smoking-related bladder cancer risk. J. Natl. Cancer Inst. 2001; 93: 538–545
   PubMed Web of Science ®Google Scholar
• Chou H. C., Lang N. P., Kadlubar F. F. Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis 1995; 16: 413–417
   PubMed Web of Science ®Google Scholar
• Clayson D. B., Lawson T. A., Santana S., Bonser G. M. Correlation between the chemical induction of hyperplasia and of malignancy in the bladder epithelium. Br. J. Cancer 1965; 19: 297
   PubMedGoogle Scholar
• Clayson D. B., Lawson T. A., Pringle J. A.S. The carcinogenic action of 2-aminodiphenylene oxide and 4-aminodiphenyl on the bladder and liver of C57 × IF mouse. Br. J. Cancer 1967; 1: 755
   Google Scholar
• Cohen S. M. The role of urinary physiology and chemistry in bladder carcinogenesis. Food. Chem. Toxicol. 1995; 33: 715–730
   PubMed Web of Science ®Google Scholar
• Cohen S. M., Ellwein L. B. Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and livercarcinogenesis: Biological modeling of the ED01 study. Toxicol. Appl. Pharmacol. 1990; 104: 79–93
   PubMed Web of Science ®Google Scholar
• Coghlin J., Gann P. H., Hammond S. K., Skipper P. L., Taghizadeh K., Paul M., Tannenbaum S. R. 4-Aminobiphenyl hemoglobin adducts in fetuses expsed to the tobacco smoke carcinogen. in utero. J. Natl. Cancer Inst. 1991; 83: 274–280
   PubMedGoogle Scholar
• Cordon-Cardo C., Reuter V. E. Alterations of tumor suppressor genes in bladder cancer. Semin. Diagn. Pathol. 1997; 14: 123–132
   PubMed Web of Science ®Google Scholar
• Curigliano G., Zhang Y. J., Wang L. Y., Flamini G., Alcini A., Ratto C., Giustacchini M., Alcini E., Cittadini A., Santella R. M. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogensis 1996; 17: 911–916
   PubMedGoogle Scholar
• Dang L. N., McQueen C. A. Mutagenicity of 4-aminobiphenyl and 4-acetylbiphenyl in Salmonella typhimurium strains expressing different levels of N-acetyltransferase. Toxicol. Appl. Pharmacol. 1999; 159: 77–82
   PubMed Web of Science ®Google Scholar
• Deichmann W. B., MacDonald W. E. The non-carcinogenicity of a single dose of 4-aminobiphenyl in the dog. Food Cosmet. Toxicol. 1968; 6: 143
   PubMedGoogle Scholar
• Deichmann W. B., Radomski J. L., Anderson W. A.D., Coplan M. M., Woods F. M. The carcinogenic action of p-aminobiphenyl in the dog. Ind. Med. Surg. 1958; 27: 25
   PubMedGoogle Scholar
• Deichmann W. B., Radomski J. L., Glass E., Anderson W. A.D, Coplan M., Woods F. M. Synergism among oral carcinogens. Simultaneous feeding of four bladder carcinogens to dogs. Ind. Med. Surg. 1965; 34: 640
   PubMedGoogle Scholar
• Del Santo P., Moneti G., Salvadori M., Saltutti C., Delle R. A., Dolara P. Levels of the adducts of 4-aminobiphenyl to hemoglobin in control subjects and bladder carcinoma patients. Cancer Lett. 1991; 60: 245–251
   PubMedGoogle Scholar
• Delclos K. B., Miller D. W., Lay J. O., Jr., Casciano D. A., Walker R. P., Fu P. P., Kadlubar F. F. Identification of C8-modified deoxyinosine and N2-and C8-modified deoxyguanosine as major products of the in vitro reaction of N-hydrozy-6-aminochrysene with DNA and the formation of these adducts in isolated rat hepatocytes treated with 6-nitrochrysene and 6-aminochrysene. Carcinogenesis 1987; 8: 1703–1709
   PubMed Web of Science ®Google Scholar
• Doerge D. R., Churchwell M. I., Marques M. M., Beland F. A. Quantitative analyses of 4-aminobiphenyl-C8-deoxyguanosyl DNA adducts produced in vitro and in vivo using HPLC-ES-MS. Carcinogenesis 1999; 6: 1055–1061
   Google Scholar
• Doerge D. R., Churchwell M. I., Marques M. M., Beland F. A. Quantitative analyses of 4-aminobiphenyl-C8-deoxyguanosyl DNA adducts produced in vitro and in vivo using HPLC-ES-MS. Carcinogenesis 1999; 6: 1055–1061
   Google Scholar
• Dooley K. L., Von Tungeln L. S., Bucci T., Fu P. P., Kadlubar F. F. Comparative carcinogenicity of 4-aminobiphenyl and the food pyrolysates, Glu-P-1, IQ, PhIP, and MeIQx in the neonatal B6C3F1 male mouse. Cancer Lett. 1992; 62: 205–209
   PubMed Web of Science ®Google Scholar
• Eaton D. L., Gallagher E. P., Bammler T. K., Kunze K. L. Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259–274
   PubMedGoogle Scholar
• Faraglia B., Chen S. Y., Gammon M. D., Zhang Y., Teitelbaum S. L., Neugut A. I., Ahsan H., Garbowski G. C., Hibshoosh H., Lin D., Kadlubar F. F., Santella R. M. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: The influence of tobacco smoke. Carcinogenesis 2003; 24: 719–725
   PubMedGoogle Scholar
• Feng Z., Hu W., Rom W. N., Beland F. A., Tang M. S. N-Hydroxy-4-aminobiphenyl-DNA binding in human p53 gene:Sequence preference and the effect of C5 cytosine methylation. Biochemistry 2002; 41: 6414–6421
   PubMedGoogle Scholar
• Flamini G., Romano G., Curigliano G., Chiominto A., Capelli G., Boninsegna A., Signorelli C., Ventura L., Santella R. M., Sgambato A., Cittadini A. 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits:an immunohistochemical study. Carcinogenesis 1998; 19: 353–357
   PubMedGoogle Scholar
• Flammang T. J., Kadlubar F. F. Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2′-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxy arylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acyltransferases. Carcinogensis 1986; 7: 919–926
   PubMed Web of Science ®Google Scholar
• Flammang T. J., Couch L. H., Levy G. N., Weber W. W., Wise C. K. DNA adduct levels in congenic rapid and slow acetylator mouse strains following chronic administration of 4-aminobiphenyl. Carcinogenesis 1992; 13: 1887–1891
   PubMed Web of Science ®Google Scholar
• Fletcher K., Tinwell H., Ashby J. Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of Muta™Mouse transgenic mice. Mutat. Res. 1998; 400: 245–250
   PubMedGoogle Scholar
• Frederickson S. M., Hatcher J. F., Reznikoff C. A., Swaminathan S. Acetyl transferase-mediated metabolic activation of N-hydroxy-4-aminobiphenyl by human uroepithelial cells. Carcinogenesis 1992; 13: 955–961
   PubMed Web of Science ®Google Scholar
• Fretland A. J., Doll M. A., Gray K., Feng Y., Hein D. W. Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) a A/HeJ (slow) acetylator inbred mouse: Functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol. Appl. Pharmacol. 1997; 142: 360–366
   PubMed Web of Science ®Google Scholar
• Gaylor D. W. The ED01 study: Summary and conclusions. J. Environ. Pathol. Toxicol. 1979; 3: 179–183
   Google Scholar
• Gorrod J. W., Carter R. L., Roe F. J.C. Induction of hepatomas by 4-aminobiphenyl and three of its hydroxylated derivatives administered to newborn mice. J. Natl. Cancer lnst. 1968; 41: 403
   PubMedGoogle Scholar
• Hammons G. J., Guengerich F. P., Weis C. C., Beland F. A., Kadlubar F. F. Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases. Cancer Res. 1985; 45: 3578–3585
   PubMed Web of Science ®Google Scholar
• Hatcher J. F., Rao K. P., Swaminathan S. Mutagenic activation of 4-aminobiphenyl and its N-hydroxy derivatives by microsomes from cultured human uroepithelial cells. Mutagenesis 1993; 8: 113–120
   PubMedGoogle Scholar
• Hatcher J. F., Swaminathan S. Microsome-mediated transacetylation and binding of N-hydroxy-4-aminobiphenyl to nucleic acids by hepatic and bladder tissues from dog. Carcinogenesis 1992; 13: 1705–1711
   PubMedGoogle Scholar
• Hatcher J. F., Swaminathan S. Detection of deoxyadenosine-4-aminobiphenyl adduct in DNA of human uroepithelial cells treated with N-hydroxy-4-aminobiphenyl following nuclease P1 enrichment and 32P-postlabeling analysis. Carcinogenesis 1995; 16: 295–301
   PubMedGoogle Scholar
• Hatcher J. F., Swaminathan S. Identification of N-(deoxyguanosin-8-yl)-4-azobiphenyl by (32)P-postlabeling analyses of DNA in human uroepithelial cells exposed to proximate metabolites of the environmental carcinogen 4-aminobiphenyl. Environ. Mol. Mutagen. 2002; 39: 314–322
   PubMedGoogle Scholar
• Hein D. W. Acetylator genotype and arylmaine-induced carcinogenesis. Biochem. Biophys. Acta 1988; 948: 37–66
   PubMed Web of Science ®Google Scholar
• Hein D. W., Grant D. M. Arylamine N-acetyltransferase (NAT) nomenclature. 2000, http://www.louisville.edu/medschool/pharmacology/NAT.html
   Google Scholar
• Hickman E. S., Moroni M. C., Helin K. The role of p53 and pRB in apoptosis and cancer. Curr. Opin. Genet. Dev. 2002; 12: 60–66
   PubMed Web of Science ®Google Scholar
• Hill A. B. The environment and disease:Association or causation?. Proc. R. Soc. Med. 1965; 58: 295–300
   PubMed Web of Science ®Google Scholar
• Hughes M. F., Smith B. J., Eling T. E. The oxidation of 4-aminobiphenyl by horseradish peroxidase. Chem. Res. Toxicol. 1992; 5: 340–345
   PubMedGoogle Scholar
• IARC. 4-Aminobiphenyl. IARC Monogr. Eval. Carcinogen. Risks Hum. 1972; 1: 74–79
   Google Scholar
• IARC. Tobacco smoking. IARC Monogr. Eval. Carcinogen. Risks Hum. 1986; 38
   Google Scholar
• IARC. 4-Aminobiphenyl (Group 1). IARC Monogr. Eval. Carcinogen. Risks Hum. Suppl. 1987; 7: 91–92
   Google Scholar
• Ioachim E., Charchanti A., Stavropoulos N. E., Skopelitou A., Athanassiou E. D., Agnantis N. J. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma. Histol. Histopathol. 2000; 15: 721–727
   PubMed Web of Science ®Google Scholar
• Ishikawa J., Xu H. J., Hu S. X., Yandell D. W., Maeda S., Kamidono S., Benedict W. F., Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res. 1991; 51: 5736–5743
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Miller J. A., Miller E. C. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 1977; 37: 805–814
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Frederick C. B., Weis C. D., Zenser T. V. Prostaglandin endoperoxide synthetase-mediated metabolism of carcinogenic aromatic amines and their binding to DNA and protein. Biochem. Biophys. Res. Commun. 1982; 108: 253–258
   PubMed Web of Science ®Google Scholar
• Kadlubar F. F., Dooley K. L., Teitel C. H., Roberts D. W., Benson R. W., Butler M. A., Bailey J. R., Young J. F., Skipper P. W., Tannenbaum S. R. Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res. 1991; 51: 4371–4377
   PubMed Web of Science ®Google Scholar
• Kimura S., Kawabe M., Ward J. M., Morishima H., Kadlubar F. F., Hammons G. J., Fernandez-Salguero P., Gonzalez F. J. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 1999; 20: 1825–1830
   PubMed Web of Science ®Google Scholar
• Koss L. G., Myron R., Melamed M. R., Kelly R. E. Further cytologic and histologic studies of bladder lesions in workers exposed to para-aminodiphenyl: Progress report. J. Natl. Cancer Inst. 1969; 43: 233
   PubMedGoogle Scholar
• Koss L. G., Myron R., Melamed M. R., Ricci A., Melick W. F., Kelly R. E. Carcinogenesis in the human urinary bladder. Observations after exposure to para-aminodiphenyl. New Engl. J. Med. 1965; 272: 767
   PubMed Web of Science ®Google Scholar
• Kriek E. Fifty years of research on N-acetyl-2-aminofluorene, one of the most versatile compounds in experimental research. J. Cancer Res. Clin. Oncol. 1992; 118: 481–489
   PubMedGoogle Scholar
• Lakshmi V. M., Mattammal M. B., Zenser T. V., Davis B. B. Mechanism of peroxidative activation of the bladder carcinogen 2-amino-4-(5-nitro-2-furyl)-thiazole (ANFT): Comparison with benzidine. Carcinogenesis 1990; 11: 1965–1970
   PubMedGoogle Scholar
• Lang M., Pelkonen O. Metabolism of xenobiotics and chemical carcinogenesis. IARC Sci. Publ. 1999; 13–22
   PubMedGoogle Scholar
• Littlefield N. A., Farmer J. H., Gaylor D. W., Sheldon W. G. Effects of dose and time in a long-term, low-dose carcinogenic study. J. Environ. Pathol. Toxicol. 1979; 3: 17–34
   Google Scholar
• Logothetis C. J., Xu H. J., Ro J. Y., Hu S. X., Sahin A., Ordonez N., Benedict W. F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer. Inst. 1992; 84: 1256–1261
   PubMed Web of Science ®Google Scholar
• Lower G. M., Jr., Nelson C. E., Wolf H., Gamsky T. E., Bryan G. T. N-Acetyltransferase phenotype and risk in urinary bladder cancer:approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 1979; 29: 71–79
   PubMed Web of Science ®Google Scholar
• Lu M. L., Wikman F., Orntoft T. F., Charytonowicz E., Rabbani F., Zhang Z., Dalbagni G., Pohar K. S., Yu G., Cordon-Cardo C. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res. 2002; 8: 171–179
   PubMed Web of Science ®Google Scholar
• Manjanatha M. G., Li E. E., Fu P. P., Heflich R. H. H-and K-ras mutational profiles in chemically induced liver tumours from B6C3F1 and CD-1 mice. J. Toxicol. Environ. Health 1996; 47: 195–208
   PubMed Web of Science ®Google Scholar
• Martone T., Airoldi L., Magagnotti C., Coda R., Randone D., Malaveille C., Avanzi G., Merletti F., Hautefeuille A., Vineis P. 4-Aminobiphenyl-DNA adducts and p53 mutations in bladder cancer. Int. J. Cancer 1998; 75: 512–516
   PubMed Web of Science ®Google Scholar
• Mattano S. S., Land S., King C. M., Weber W. W. Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: Identify with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-Acetyltransferase. Mol. Pharmacol. 1989; 68: 599–609
   Google Scholar
• McQueen C. A., Chau B., Erickson R. P., Tjalkens R. B., Philbert M. A. The effects of genetic variation in N-acetyltransferases on 4-aminobiphenyl genotoxicity in mouse liver. Chem. Biol. Interact. 2003; 146: 51–60
   PubMedGoogle Scholar
• Melamed M. R., Koss L. G., Ricci A., Whitmore W. F. Cytohistological observations on developing carcinoma of urinary bladder in man. Cancer (Phila.) 1960; 13: 67
   Web of Science ®Google Scholar
• Melick W. F., Escue H. M., Naryka J. J., Mezera R. A., Wheeler E. R. The first reported cases of human bladder tumors due to a new carcinogen—Xenylamine. J. Urol. (Baltimore) 1955; 74: 760
   PubMed Web of Science ®Google Scholar
• Melick W. F., Naryka J. J., Kelly R. E. Bladder cancer due to exposure to para-aminobiphenyl: A 17-year follow-up. J. Urol. (Baltimore) 1971; 106: 220
   PubMed Web of Science ®Google Scholar
• Merck Veterinary Manual. 1998
   Google Scholar
• Miller J. C., Miller E. C. Ultimate chemical carcinogens as reactive mutagenic eletrophiles. Origins of Human Cancer, H. H. Hiatt, J. D. Watson, J. A. Winsten. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1977; 605–627
   Google Scholar
• Miller J. A., Wyatt C. S., Miller E. C., Hartmann H. A. The N-hydroxylation of 4-acetylaminobiphenyl by the rat and dog and the strong carcinogenicity of N-hydroxy-4-acetylaminobiphenyl in the rat. Cancer Res 1961; 21: 1465
   Web of Science ®Google Scholar
• Oda Y. Analysis of the involvement of human N-acetyltransferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system. Mutat. Res. 2004; 554: 399–406
   PubMedGoogle Scholar
• Oscarson M., Ingelman-Sundberg M., Daly A. K., Nebert D. W. Human Cytochrome P450 (CYP) Allele Nomenclature Committee, http//www.imm.ki.se/CYPalleles/
   Google Scholar
• Parsons B. L., Culp S. J., Manjanatha M. G., Heflich R. H. Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression. Carcinogenesis 2002; 23: 943–948
   PubMedGoogle Scholar
• Parsons B. L., Beland F. A., Von Tungeln L. S., Delongchamp R. R., Fu P., Heflich R. H. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver correlate with potential for liver tumor development. Mol. Carcinogen. 2005; 42: 193–201
   PubMedGoogle Scholar
• Pauli B. U., Alroy J., Weinstein R. S. The ultrastructure and pathobiology of urinary bladder cancer. The Pathology of Bladder Cancer, Vol. II, G. T. Bryan, S. M. Cohen. CRC Press, Boca Raton, FL 1983; 41–140
   Google Scholar
• Poirier M. C., Beland F. A. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: Implications for DNA adduct-based human cancer risk assessment. Chem. Res. Toxicol. 1992; 5: 749–755
   PubMed Web of Science ®Google Scholar
• Poirier M. C., Fullerton N. F., Smith B. A., Beland F. A. DNA adduct formation and tumorigenesis in mice during the chronic administration of 4-aminobiphenyl at multiple dose levels. Carcinogenesis 1995; 16: 2917–2921
   PubMed Web of Science ®Google Scholar
• Presti J. C.J., Reuter V. E., Galan T., Fair W. R., Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 1991; 51: 5405–5409
   PubMed Web of Science ®Google Scholar
• Primdahl H., von der M., Christensen M., Wolf H., Orntoft T. F. Allelic deletions of cell growth regulators during progression of bladder cancer. Cancer Res. 2000; 60: 6623–6629
   PubMed Web of Science ®Google Scholar
• Reznikoff C. A., Loretz L. J., Johnson M. D., Swaminathan S. Quantitative assessments of the cytotoxicity of bladder carcinogens towards cultured normal human uroepithelial cells. Carcinogenesis 1986; 7: 1625–1632
   PubMedGoogle Scholar
• Roberts D. W., Benson R. W., Groopman J. D., Flammang T. J., Nagle W. A., Moss A. J., Kadlubar F. F. Immunochemical quantitation of DNA adducts derived from the human bladder carcinogen 4-aminobiphenyl. Cancer Res. 1988; 48: 6336–6342
   PubMedGoogle Scholar
• Sachse C., Bhambra U., Smith G., Lightfoot T. J., Barrett J. H., Scollay J., Garner R. C., Boobis A. R., Wolf C. R., Gooderham N. J., Colorectal Cancer Study Group. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: Allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol 2003; 55: 68–76
   PubMed Web of Science ®Google Scholar
• Sarkar M. A., Nseyo U. O., Zhong B.-Z. Mutagenic outcome of the urinary carcinogen 4-aminobiphenyl is increased in acidic pH. Environ. Toxicol. Pharmacol. 2002; 11: 23–26
   PubMedGoogle Scholar
• Schieferstein G. J., Littlefield N. A., Gaylor D. W., Sheldon W. G., Burgers G. T. Carcinogenesis of 4-aminobiphenyl in BALB/cStCrlfC3Hf/Nctr mice. Eur. J. Cancer Clin. Oncol. 1985; 21: 865–873
   PubMedGoogle Scholar
• Schroeder J. C., Conway K., Li Y., Mistry K., Bell D. A., Taylor J. A. p53 mutations in bladder cancer: Evidence for exogenous versus endogenous risk factors. Cancer Res. 2003; 63: 7530–7538
   PubMed Web of Science ®Google Scholar
• Sesardic D., Boobis A. R., Edwards R. J., Davies D. S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 1988; 26: 363–372
   PubMed Web of Science ®Google Scholar
• Skipper P. L., Tannenbaum S. R., Ross R. K., Yu M. C. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 503–507
   PubMed Web of Science ®Google Scholar
• Smith B. J., Curtis J. F., Eling T. E. Bioactivation of xenobiotics by prostaglandin H synthase. Chem. Biol. Interact. 1991; 79: 245–264
   PubMed Web of Science ®Google Scholar
• Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Krose D., Mangelsdorf I., Meek E., Rice J. M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001; 34: 146–152
   PubMed Web of Science ®Google Scholar
• Swaminathan S. A. Metabolism and nucleic acid finding of N-hydroxy-4-acetylaminobiphenyl and N-acetyoxy-4-acetylaminibiphenyl bu cultured human uroepithelial cells. Cancer Res 1992; 52: 3286–3294
   PubMedGoogle Scholar
• Talaska G., Dooley K. L., Kadlubar F. F. Detection and characterization of carcinogen–DNA adducts in exfoliated urothelial cells from 4-aminobiphenyl-treated dogs by 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography. Carcinogenesis 1990; 11: 639–646
   PubMed Web of Science ®Google Scholar
• Tiguert R., Bianco F. J.J., Oskanian P., Li Y., Grignon D. J., Wood D. P.J., Pontes J. E., Sarkar F. H. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. J. Urol. 2001; 166: 2155–2160
   PubMedGoogle Scholar
• Tsuneoka Y., Dalton T. P., Miller M. L., Clay C. D., Shertzer H. G., Talaska G., Medvedovic M., Nebert D. W. 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(−/−) and Cyp1a2(+/+) mice. J. Natl. Cancer Inst. 2003; 95: 1227–1237
   PubMed Web of Science ®Google Scholar
• Underwood P. M., Zhou Q., Jaeger M., Reilman R., Pinney S., Warshawsky D., Talaska G. Chronic, topical administration of 4-aminobiphenyl induces tissue-specific DNA adducts in mice. Toxicol. Appl. Pharmacol. 1997; 144: 325–331
   PubMedGoogle Scholar
• Verghis S. B.M., Essigmann J. M., Kadlubar F. F., Morningstar M. L., Lasko D. D. Specificity of mutagenesis by 4-aminobiphenyl: Mutations at G residues in bacteriophage M13 DNA and G→C transversions at a unique dG8-ABP lesion in single-stranded DNA. Carcinogenesis 1997; 18: 2403–2414
   PubMed Web of Science ®Google Scholar
• Vineis P., Caporaso N., Tannenbaum S. R., Skipper P. L., Glogowski J., Bartsch H., Coda M., Talaska G., Kadlubar F. F. Acetylation phenotype, carcinogen–hemoglobin adducts, and cigarette smoking. Cancer Res. 1990; 50: 3002–3004
   PubMed Web of Science ®Google Scholar
• Von Tungeln L. S., Bucci T. J., Hart R. W., Kadlubar F. F., Fu P. P. Inhibitory effect of caloric restriction on tumorigenicity induced by 4-aminobiphenyl and 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) in the CD1 newborn mouse bioassay. Cancer Lett. 1996; 104: 133–136
   PubMed Web of Science ®Google Scholar
• Vousden K. H., Lu X. Live or let die: The cell's response to p53. Nat. Rev. Cancer 2002; 2: 594–604
   PubMed Web of Science ®Google Scholar
• Walpole A. L., Williams M. H.C., Roberts D. C. The carcinogenic action of 4-aminodiphenyl and 3:2'-dimethyl-4-aminodiphenyl. Br. J. Ind. Med. 1952; 9: 255
   PubMedGoogle Scholar
• Walpole A. L., Williams M. H.C., Roberts D. C. Tumours of the urinary bladder in dogs after ingestion of 4-aminodiphenyl. Br. J. Ind. Med 1954; 11: 105
   PubMedGoogle Scholar
• Weston A., Caporaso N. E., Taghizadeh K., Hoover R. N., Tannenbaum S. R., Skipper P. L., Resau J. H., Trump B. F., Harris C. C. Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls. Cancer Res. 1991; 51: 5219–5223
   PubMedGoogle Scholar
• Wright C., Thomas D., Mellon K., Neal D. E., Horne C. H. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: Correlation with Ki67 index. Br. J. Urol. 1995; 75: 173–179
   PubMedGoogle Scholar
• Wu X. R., Lin J. H., Walz T., Haner M., Yu J., Aebi U., Sun T. T. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J. Biol. Chem. 1994; 269: 13716–13724
   PubMedGoogle Scholar